Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

Biotech takes aim at large anti-estrogen markets

Nature Biotechnology volume 24, pages 1455–1456 (2006)Cite this article

Next year, San Diego-based Ligand Pharmaceuticals is hoping to launch a third-generation selective estrogen receptor modulator (SERM) that it developed with Wyeth of Collegeville, Pennsylvania.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Boston

    Mark Hollmer

Authors
  1. Mark Hollmer
    View author publications

    You can also search for this author in PubMed Google Scholar

Related links

Related links

Web links

Ligand Pharmaceuticals

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hollmer, M. Biotech takes aim at large anti-estrogen markets. Nat Biotechnol 24, 1455–1456 (2006). https://doi.org/10.1038/nbt1206-1455

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1206-1455

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing